Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

Giandomenico Roviello; Daniele Generali

doi:10.2174/1568009616666151106120716

ISSN: 1568-0096
E-ISSN: 1873-5576

Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
By Giandomenico Roviello and Daniele Generali
Source: Current Cancer Drug Targets, Volume 16, Issue 3, Mar 2016, p. 209 - 214
DOI: https://doi.org/10.2174/1568009616666151106120716
- Available online: 01 Mar 2016

Abstract

It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.

Article metrics loading...

/content/journals/ccdt/10.2174/1568009616666151106120716

2016-03-01

2025-09-02

From This Site

/content/journals/ccdt/10.2174/1568009616666151106120716

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/content/journals/ccdt/10.2174/1568009616666151106120716

Article Type: Research Article

Keyword(s): Bevacizumab; lung cancer; maintenance; small cell

Most Cited Most Cited RSS feed

- Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
  
  Authors: Yong Lin, Ranxin Shi, Xia Wang and Han-Ming Shen
- The Role of Snail in EMT and Tumorigenesis
  
  Authors: Yifan Wang, Jian Shi, Kequn Chai, Xuhua Ying and Binhua P. Zhou
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
  
  Authors: Amancio Carnero, Carmen Blanco-Aparicio, Oliver Renner, Wolfgang Link and Juan F.M. Leal
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
  
  Authors: D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou
- P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
  
  Authors: Ziyad Binkhathlan and Afsaneh Lavasanifar
- Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
  
  Authors: M. Abal, J.M. Andreu and I. Barasoain
- Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
  
  Authors: R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson and M.V. Seiden
- The Role of Fibroblast Growth Factors in Tumor Growth
  
  Authors: M. Korc and R. E. Friesel
- Garlic [Allium sativum]: A Review of its Potential Use as an Anti-Cancer Agent
  
  Authors: M. Thomson and M. Ali
- Oxidative Stress and Cancer: The Role of Nrf2
  
  Authors: Soraya Sajadimajd and Mozafar Khazaei
More Less

Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

Abstract

Most Read This Month

Most Cited Most Cited RSS feed